title: The basics of CAR T design and challenges in immunotherapy of solid tumors - Ovarian cancer as a model.
abstract: Chimeric antigen receptor T cells are T cells genetically engineered with CAR constructs which mainly contain scFV and TCR zeta chain. With promising development in blood cancers, CAR T trials are also applied in solid cancers. However, the treatment effect in solid cancers is lower than expected. This review summarizes difference of CAR T applications in solid and blood cancers. Future challenges of CAR T cell treatment in solid cancer are also discussed using ovarian cancer as an example.
authors.affiliation: a Department of Obstetrics and Gynecology , Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University , Shanghai , China.
authors.forename: Xuequn
authors.initials: X
authors.lastname: Xu
authors.affiliation: a Department of Obstetrics and Gynecology , Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University , Shanghai , China.
authors.forename: Jin
authors.initials: J
authors.lastname: Qiu
authors.affiliation: a Department of Obstetrics and Gynecology , Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University , Shanghai , China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Sun
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D010051:Ovarian Neoplasms / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000378:metabolism*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D011948:Receptors, Antigen, T-Cell
keywords: FAS/FASL; activation induced cell death (AICD); blood cancer; chimeric antigen receptor T cells (CAR T); clinical trial; mesothelin; ovarian cancer; solid cancer